Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study.
暂无分享,去创建一个
B. Crompton | C. Roberts | K. Stegmaier | L. Macconaill | M. Harris | N. Lindeman | L. Diller | C. Rodríguez-Galindo | W. London | K. Janeway | J. G. Glade Bender | S. Shusterman | A. Hong | S. DuBois | A. Kim | Erin Parker | A. Church | Ian P Dumont | D. Guo | Dongjing Guo
[1] W. Hahn,et al. Prospective enterprise-level molecular genotyping of a cohort of cancer patients. , 2014, The Journal of molecular diagnostics : JMD.
[2] P. Stephens,et al. Abstract A23: Comprehensive next-generation sequencing-based genomic profiling identifies actionable genomic alterations in diverse pediatric tumor types: The Foundation Medicine (FMI) experience , 2014 .
[3] Adam Kiezun,et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma , 2014, Proceedings of the National Academy of Sciences.
[4] A. McKenna,et al. The genomic landscape of pediatric Ewing sarcoma. , 2014, Cancer discovery.
[5] John N. Weinstein,et al. PRADA: pipeline for RNA sequencing data analysis , 2014, Bioinform..
[6] G. Getz,et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. , 2014, Cancer discovery.
[7] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[8] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[9] Steven J. M. Jones,et al. The genetic landscape of high-risk neuroblastoma , 2013, Nature Genetics.
[10] C. Bacchi,et al. Cutaneous Clear Cell Sarcoma: Report of Three Cases of a Potentially Underestimated Mimicker of Spindle Cell Melanoma , 2012, The American Journal of dermatopathology.
[11] Nikhil Wagle,et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. , 2012, Cancer discovery.
[12] A. Nicholson,et al. Primary Pulmonary Myxoid Sarcoma With EWSR1-CREB1 Fusion: A New Tumor Entity , 2011, The American journal of surgical pathology.
[13] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[14] Keith L. Ligon,et al. Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples , 2009, PloS one.
[15] S. Henikoff,et al. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.
[16] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[17] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.